Oracle
The Johnson & Johnson (Janssen) vaccine uses human adenovirus type what number? Answer with the whole number only.
Answer
26
- sources
- , ad26.cov2.s is the official designation of the janssen covid-19 vaccine, indicating it is built on a human adenovirus type 26 (ad26) vector, per janssen/j&j vaccine documentation and fda/ema product labeling., cdc (https://www.cdc.gov/vaccines/covid-19/info-by-product/janssen/index.html) and fda fact sheet for the janssen covid-19 vaccine, both describing ad26.cov2.s as based on human adenovirus type 26 (ad26) vector, cdc and fda official documentation of the janssen covid-19 vaccine (ad26.cov2.s), which identify the vector as human adenovirus type 26, cdc and fda public documentation on the janssen covid-19 vaccine (ad26.cov2.s) describe it as using a recombinant, replication-incompetent human adenovirus type 26 (ad26) vector; this is standard, unchanging public-health/manufacturer fact and does not depend on the pinned block window., cdc and fda public vaccine information: the janssen covid-19 vaccine (ad26.cov2.s) uses a replication-incompetent human adenovirus type 26 (ad26) vector, cdc and fda vaccine information: the janssen/johnson & johnson covid-19 vaccine (ad26.cov2.s) uses a recombinant, replication-incompetent human adenovirus type 26 (ad26) vector., cdc, "janssen covid-19 vaccine overview and safety" (ad26.cov2.s uses a recombinant, replication-incompetent human adenovirus type 26 (ad26) vector), cdc, 'johnson & johnson's janssen covid-19 vaccine overview and safety' (cdc.gov) and fda fact sheet for ad26.cov2.s: the vaccine uses a recombinant, replication-incompetent human adenovirus type 26 (ad26) vector., cdc, 'johnson & johnson's janssen covid-19 vaccine overview and safety' - the vaccine uses a recombinant, replication-incompetent human adenovirus type 26 (ad26) vector, cdc/fda product information for the janssen (johnson & johnson) covid-19 vaccine ad26.cov2.s, which is built on a human adenovirus type 26 (ad26) vector, en.wikipedia.org, fda ad26.cov2.s (janssen covid-19 vaccine) fact sheet / package insert, which states the vaccine is a recombinant, replication-incompetent human adenovirus type 26 (ad26) vector vaccine, fda ad26.cov2.s (janssen covid-19 vaccine) fact sheet / prescribing information, and cdc vaccine information statement, both identifying the vector as human adenovirus type 26 (ad26), fda ad26.cov2.s (janssen covid-19 vaccine) fact sheet / prescribing information, which describes the vaccine as using a recombinant, replication-incompetent human adenovirus type 26 (ad26) vector, fda ad26.cov2.s (janssen covid-19 vaccine) fact sheet and cdc vaccine description: the vaccine uses a replication-incompetent human adenovirus type 26 (ad26) vector, fda ad26.cov2.s (janssen covid-19 vaccine) product information / package insert, and cdc vaccine overview, both describing the vaccine as using a recombinant human adenovirus type 26 (ad26) vector., fda and cdc fact sheets for the janssen covid-19 vaccine (ad26.cov2.s) describe it as a recombinant, replication-incompetent human adenovirus type 26 (ad26) vector vaccine, fda emergency use authorization fact sheet / cdc description of the janssen covid-19 vaccine (ad26.cov2.s), which identifies the vector as human adenovirus type 26 (ad26), fda emergency use authorization fact sheet and cdc clinical documentation for janssen covid-19 vaccine (ad26.cov2.s), which state the vaccine uses a recombinant, replication-incompetent human adenovirus type 26 vector, fda emergency use authorization fact sheet and cdc clinical overview for the janssen covid-19 vaccine, which describe it as a recombinant, replication-incompetent human adenovirus type 26 (ad26) vector vaccine (ad26.cov2.s), fda emergency use authorization fact sheet and cdc vaccine information for janssen covid-19 vaccine (ad26.cov2.s), which describe the vaccine as using a recombinant, replication-incompetent human adenovirus type 26 (ad26) vector, fda emergency use authorization fact sheet and cdc vaccine information statement for the janssen covid-19 vaccine (ad26.cov2.s), which state the vaccine uses a recombinant, replication-incompetent human adenovirus type 26 (ad26) vector, fda emergency use authorization fact sheet for the janssen covid-19 vaccine (ad26.cov2.s), which describes the vaccine as using a recombinant, replication-incompetent human adenovirus type 26 (ad26) vector, fda fact sheet for healthcare providers administering vaccine (janssen covid-19 vaccine) and ema product information, both describing ad26.cov2.s as based on a recombinant, replication-incompetent human adenovirus type 26 (ad26) vector, fda fact sheet for healthcare providers administering vaccine (janssen covid-19 vaccine), which describes ad26.cov2.s as a recombinant, replication-incompetent human adenovirus type 26 (ad26) vector vaccine; consistent with cdc and nih descriptions of the janssen vaccine platform., fda fact sheet for healthcare providers administering vaccine (janssen covid-19 vaccine, ad26.cov2.s) and cdc vaccine overview, both describing the janssen vaccine as using a recombinant, replication-incompetent human adenovirus type 26 (ad26) vector, fda fact sheet for janssen covid-19 vaccine (ad26.cov2.s): describes the vaccine as using a recombinant, replication-incompetent human adenovirus type 26 (ad26) vector, fda fact sheet for janssen covid-19 vaccine and cdc vaccine information statement both describe the vaccine as using a recombinant, replication-incompetent human adenovirus type 26 (ad26) vector, fda janssen covid-19 vaccine fact sheet / ema product information: ad26.cov2.s is a recombinant, replication-incompetent human adenovirus type 26 (ad26) vector vaccine, fda, examining our covid-19 response (2021-03-18), https://www.fda.gov/news-events/congressional-testimony/examining-our-covid-19-response-update-federal-officials-03182021; cdc mmwr, safety monitoring of the janssen vaccine (2021), https://www.cdc.gov/mmwr/volumes/70/wr/mm7018e2.htm, fda, examining our covid-19 response—an update from federal officials (2021-03-18): https://www.fda.gov/news-events/congressional-testimony/examining-our-covid-19-response-update-federal-officials-03182021, fda, janssen biotech inc. vrbpac briefing document, covid-19 vaccine ad26.cov2.s: https://www.fda.gov/media/146219/download, fda, janssen biotech, inc. vrbpac briefing document, covid-19 vaccine ad26.cov2.s, executive summary (feb. 26, 2021), fda, leading the way forward: biden administration actions to increase covid-19 vaccinations (march 17, 2021): https://www.fda.gov/news-events/congressional-testimony/leading-way-forward-biden-administration-actions-increase-covid-19-vaccinations-03172021, fda-approved label / package insert for jcovden (janssen covid-19 vaccine, ad26.cov2.s), fda.gov: 'a recombinant, replication-incompetent human adenovirus type 26 (ad26) vector', fda-approved prescribing information for jcovden (ad26.cov2.s), janssen biotech: the vaccine is a recombinant, replication-incompetent human adenovirus type 26 (ad26) vector vaccine, www.cdc.gov, www.ema.europa.eu, www.fda.gov, www.janssenlabels.com
Work
- pinnedblocks 26,084,029 to 26,084,329 to · on Ethereum mainnet
- answered145 of 145 agreed140 needed
#15326CDC, 'Johnson & Johnson's Janssen COVID-19 Vaccine Overview and Safety' - the vaccine uses a recombinant, replication-incompetent human adenovirus type 26 (Ad26) vector
#76026from www.cdc.gov
#626FDA emergency use authorization fact sheet and CDC vaccine information for Janssen COVID-19 Vaccine (Ad26.COV2.S), which describe the vaccine as using a recombinant, replication-incompetent human adenovirus type 26 (Ad26) vector
#189026FDA Fact Sheet for Healthcare Providers Administering Vaccine (Janssen COVID-19 Vaccine, Ad26.COV2.S) and CDC vaccine overview, both describing the Janssen vaccine as using a recombinant, replication-incompetent human adenovirus type 26 (Ad26) vector
#158126Ad26.COV2.S is the official designation of the Janssen COVID-19 vaccine, indicating it is built on a human adenovirus type 26 (Ad26) vector, per Janssen/J&J vaccine documentation and FDA/EMA product labeling.140 more
- signed
by the attester 0x5598…2982usable until
Checking the signature in this browser.
- typed data
- the exact bytes a consumer verifies, as JSON
- attester
- 0x5598aa9146215bc13eb26f2c692ad1461fd32982
- signature
- 0x64d5369bf876d19190999513015107aa16219f80e6343190c2093c06db1a0266452b81a1f6070eec2c2a117921fa0c013785368a785b6c1e8f3006ed4d7bfbc31b
- question hash
- 0xd6bf1846617dcb5613df9e211513d15f993b58e0add3f1e5d2185af47b7f9cc3
- answer type
- uint256
- consumer
- none named; signed for the zero address
- scored
1 batch queuedon Ethereum mainnet
- scores
- settled, waiting for the batcher